arrow
R

Rogério Serafim Parra

University of São Paulo
H指数:19
被引数:1,365

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical characteristics associated with advanced therapy optimization in inflammatory bowel disease in the Brazilian GEDIIB national registry

与巴西GEDIIB国家登记中炎症性肠病高级疗法优化相关的临床特征

2026-09-200
OAAI
Real-World Comparative Effectiveness and Safety of Ustekinumab Versus Anti-TNF Agents as First- or Second-Line Biologics in Crohn's Disease: A Multicenter Observational Study

真实世界中,乌司木单抗相较于抗-TNF药物的作为克罗恩病的一线或二线生物制剂的疗效与安全性比较:一项多中心观察性研究

2025-12-010
PRE
Prior Exposure to Biologics and its Impact on Outcomes in Ulcerative Colitis: An Integrated Analysis of a Brazilian Cohort

既往生物制剂暴露及其对溃疡性结肠炎结局的影响:一项巴西队列的整合分析

2025-12-010
PRE
Real-World Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Retrospective Cohort Study

奥博珠单抗在溃疡性结肠炎患者中的真实世界有效性与安全性:一项回顾性队列研究

2025-10-010
OAAI
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

托法替尼治疗溃疡性结肠炎的巴西研究:一项关于有效性和安全性的多中心观察性研究

2025-03-180
OA
Factors Associated with the Optimization of Biological Therapy in Crohn's Disease and Ulcerative Colitis: Insights from the National GEDIIB Patient Registry in Brazil
2025-01-220
PRE
Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
2024-12-010
OA
Clinical factors associated with severity in patients with inflammatory bowel disease in Brazil based on 2-year national registry data from GEDIIB
2024-02-211
OAAI
Evaluation of the Quality-of-Care Parameters in Patients With Inflammatory Bowel Disease in Brazilian Hospitals
2023-12-010
OA
Clinical Profile of Patients With Inflammatory Bowel Disease in Brazil: Analysis of the National Registry (GEDIIB)
2023-12-010
OA
Divergent androgenic modulation of SARS-CoV-2 infection cooperates with dysregulated immune response to dictate worse COVID-19 outcomes in men
2023-11-012
PRE
Plasma Sphingomyelin Disturbances: Unveiling Its Dual Role as a Crucial Immunopathological Factor and a Severity Prognostic Biomarker in COVID-19
CELLS
IF5.2
2023-07-264
OAAI
Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction-A Prospective Trial
2023-06-193
OAAI